LOW-DOSE NALTREXONE (LDN) FACTS
Naltrexone is an opioid antagonist used primarily in the management of alcohol and opioid dependence; the FDA approved Naltrexone in 1984 at 50mg. However, “Accumulating evidence suggests LDN can promote health supporting immune- modulation, which reduces various oncogenic inflammatory autoimmune processes.”1
The value of Naltrexone as an immune modulator was recognized by Dr. Ian Zagon at the University of Pennsylvania.2,3 The late Dr. Bernard Bihari, a Neurophysician from New York, USA (who passed away on May 16th, 2010) began treating his patients in the late 1980s4,5. Since that time, many doctors throughout the United States prescribe LDN for a number of indications including Multiple Sclerosis (MS), Parkinson’s disease, Crohn’s disease, HIV/AIDS, cancer and other autoimmune and inflammatory diseases.
A number of research and clinical trials have been completed and undergone in regards to LDN immunotherapies, with phase I and phase II clinical trials successfully run at a number of universities in the United States and Europe, including Pennsylvania State University Medical School at Hershey; University of Chicago; State University of New York; SUNY Upstate Medical University; London Health Sciences Centre – University Hospital, USA; Alpert Medical School of Brown University; Department of Neurology, San Raffaele Scientific Institute; Division of Rheumatology, St. Louis College of Pharmacy; Department of Internal Medicine, University of Utah; Jondi-Shapoor University of Medical Sciences; Department of Psychiatry & Behavioral Sciences, Duke University Medical Center; and Multiple Sclerosis Center at UCSF6. These efforts were pioneered by leading immunologists Dr. Nicholas Plotnikoff, Dr. Ronald Herberman, Dr. Bernard Bihari, Dr. Angus Dalgleish, Dr. Ian S. Zagon, Dr. Jill Smith, Dr. McLaughlin, Dr. Jacqueline
McCandless, and Moshe Rogosnitzky, among others.
Get access to the LDN Study Database
How LDN Works
The mechanism of action of naltrexone, in autoimmune diseases and cancer, is still being researched, but there are theories as to the mechanism of action that both explain why LDN works on both autoimmune diseases and cancers, as well as inflammatory disease.
According to Mark J. Donahue’s paper on LDN that uses interviews from Dr. David, Gluck, Dr. Jacquelyn McCandless, Dr. Jarred Younger, and Dr. Ian Zagon:
“LDN is an opioid antagonist that not only blocks the reception of opiates, but also the body’s own endogenous opioids – endorphins. However, because LDN is administered in such a ‘low dose’ it is believed that LDN only briefly (for 3-4 hours) obstructs the effects
of endorphins. Sensing an endorphin deficit, the hypothalamus signals for increased production of endorphins in what is called ‘the rebound effect.’ The rebound effect results in three things happening:
- Opioid receptor production increases in order to try and capture more endorphins.
- Opioid receptor sensitivity increases, also in order to try and capture more endorphins.
- Production of endorphins is increased in order to compensate for the perceived shortage.
Once LDN is metabolized by the liver and eliminated from the body (after 3-4 hours), the elevated levels of endorphins produced, as a result of the rebound effect, can now interact and bind with the more sensitive and more plentiful opioid receptors. These opioid receptors, are found throughout the body, including virtually every cell of the body’s immune system.
The elevated levels of endorphins will usually last around 18-20 hours. During this time the elevated endorphins act by up-regulating vital elements of the body’s immune cells. By doing so clinical trials has been shown that elevated levels of
- Down regulating inflammatory cytokines
- Reducing inflammation and oxidative stress
- Facilitating tissue repair and wound healing
- Restoring T-helper/CD4 levels
Restoring the balance between Th1 & Th2 lymphocytes
- Increasing cytotoxic T cells and natural killer (NK) cells
- Regulating cell growth & inhibiting tumor growth
- Reducing excitotoxicity and microglial activation
- Reducing apoptosis of the myelin-producing oligodendrocytes
- Stimulating mucosal healing (lining of bowel)”7
According to Dr. Nancy Sajben in an article she wrote about LDN, she explains it’s mechanism as follows:
“In 2008 in the US and UK have shown that naltrexone in addition to binding to the opiate receptor’s binds to naltrexone in addition to binding to the opiate receptor’s binds to Toll Like Receptors (TLR),. There are 13 TLRs, and so far they have studied naltrexone only in two of them TRL4 and TRL9. That is important because the TLR receptors are part of the innate immune system and effect the inflammatory markers.
The Toll Like Receptors are not like other receptors. They are not these snug little pockets where naltrexone binds. Instead the Toll Like Receptors are like an entire football field, with enormous nooks and crannies where it has many interactions with many molecules. Now, in 2010, scientists are asking if naloxone or naltrexone is acting at TLR4 or even higher up in the cascade.
The study of immune cell glial interactions is in its infancy. Glial cells are the immune cells in your central nervous system (brain, spinal cord). They are very involved in dysregulation of pain systems, neuroinflammation, and some neurological diseases such as Multiple Sclerosis, Alzheimer’s, Parkinson ’s disease, Autism, ALS, infections of the brain, etc.”
The Conditions We Treat With LDN:
There are a number of conditions where LDN could benefit based on clinical studies and patient data.
Published Clinical Studies:
|• Crohn’s Diseases||• Multiple Sclerosis|
|• Fibromyalgia||• HIV/AIDS|
|• Melanoma,||• Prostate Cancer|
|• Cervical Cancer||• Autism|
|• Ulcerative Colitis||• Hepatoblastoma|
|• Chemo Resistant AdvancedCarcinoma||• Metastatic Breast|
|• Glioma Patients||• Gulf War Syndrome|
|• Complex Regional Pain Syndrome||• Pruritus in Systemic Sclerosis|
|• Gastrointestinal Disorders||• Irritable Bowel Syndrome|
|• Low-dose naltrexone for disease prevention and quality of life||• Low Dose Naltrexone (LDN) Immune Monitoring (LDNIM)|
For a list of current ongoing LDN studies, click here.
Patients Have Also Reported Help With:
|• Malaria||• Epstein-Barr Syndrome|
|• Hepatitis C||• Lung Cancer|
|• Rheumatoid Arthritis||• Bladder Cancer|
|• Systemic Lupus Erythematosus||• Breast Cancer|
|• Parkinson’s Disease||• Lymphoma (Hodgkin’s and Non|
|• Wound Healing||• Hodgkin’s) Colon & Rectal Cancer|
|• Malignant Melanoma||• Uterine Cancer|
|• Glioblastoma||• Throat Cancer|
|• Liver Cancer||• Neuroblastoma|
|• Multiple Myeloma||• Renal Cell Carcinoma|
|• Ovarian Cancer|
Our compressed LDN tablet has a 99.9% specificity as to product and dosage whereas the other sources in the world are in capsule form from compound pharmacies and at best are 80-90% specific. The clinical results between our standard brand and the generic capsule form are world’s apart.
If you would like to contact us regarding questions about LDN